Immune Evasion in Pancreatic Cancer: from Mechanisms to Therapy
Preprint
- 4 December 2017
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Pancreatic ductal adenocarcinoma (PDA), the most frequent type of pancreatic cancer, is one of the main unfinished businesses in the biomedical and clinical fields, with still discouraging 5 year survival rates and poor therapy efficiency. PDA abundant desmoplasia has for long played the lead in the mechanisms involved in poor drug performance, being the main source of cytokines and chemokines orchestrating rapid and silent tumor progression and guilty of isolating tumor cells into a extense fibrotic reaction resulting in inefficient drug delivery. However, since immunotherapy was proclaimed the breakthrough of the year back to 2013, the focus in the stroma of pancreatic cancer has interestingly moved from activated fibroblasts to the immune compartment, trying to understand the immunosuppressive factors that play part in the strong immune evasion that characterizes PDA. PDA microenvironment is highly immune-suppressive, being basically composed of T regulatory cells (Tregs), tumor-associated macrophages (TAMs) and myeloid-derived suppressive cells (MDSCs), which boycott CD8+ T-cell duties in tumor recognition and clearance. Interestingly, preclinical data have highlighted the importance of this immune evasion as the source of resistance to single checkpoint immunotherapies and cancer vaccines and point at pathways inhibiting the immune attack as the key to solve the therapy puzzle. Here, we will discuss the molecular mechanisms involved in PDA immune escape as well as the state of the art of the PDA immunotherapy.Keywords
All Related Versions
This publication has 122 references indexed in Scilit:
- CAR T‐cell therapy for pancreatic cancerJournal of Surgical Oncology, 2017
- Galectin‐1 Triggers Epithelial‐Mesenchymal Transition in Human Hepatocellular Carcinoma CellsJournal of Cellular Physiology, 2014
- Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functionsCancer Immunology, Immunotherapy, 2013
- High expression of Galectin‐1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancerInternational Journal of Cancer, 2011
- Novel roles of galectin-1 in hepatocellular carcinoma cell adhesion, polarization, and in vivo tumor growthHepatology, 2011
- Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancersCancer Immunology, Immunotherapy, 2008
- Defective death receptor signaling as a cause of tumor immune escapeSeminars in Cancer Biology, 2002
- Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinomaInternational Journal of Cancer, 2001
- Role of transforming growth factor beta in cancerJournal of Cellular Physiology, 2001
- IL6 and IL6 receptor expression in Burkitt's lymphoma and lymphoblastoid cell lines: Promotion of IL6 receptor expression by EBVHematological Oncology, 1995